IRDye® 800CW PEG Fluorescent Contrast Agent

IRDye 800CW PEG Contrast Agent Detects EPR in Tumor Vasculature.

IRDye 800CW PEG Contrast Agent (25-60 kDa) is a non-specific imaging agent intended to exploit enhanced permeability and retention (EPR) in tumor biology.

EPR is a common characteristic of tumor vasculature. The vascular endothelium in the tumor microenvironment is often discontinuous, allowing molecules to diffuse into the surrounding tumor tissue.1, 2 In addition to EPR, the lymphatic drainage for these regions is poor.3 Hence, larger molecules tend to accumulate.

Learn more about LI-COR optical probes.

Applications

Absorbance and Emission Spectra

Data Examples

In appropriate mouse models, the agent highlights surface vasculature for approximately 0.5 hour post-injection as seen in Figure 1. Approximately 4 hours post-injection, retention of the labeled macromolecule is visible in the tumor (Figure 2). At 9 hours post-intravenous injection the tumor is well defined (Figure 3).

IRDye 800CW PEG Contrast Agent may also be used effectively as a lymph tracking agent when given intradermally (Figure 4). Images captured on the Pearl® Imaging System.

Figure 1. Athymic male nu/nu mouse (~5-6 wks old) 0.5 hour after receiving IRDye 800CW PEG (1 nmol) intravenously. Surface blood vessels are visible. Vascular feature is mouse model dependent, see pack insert for Precautions.
Figure 2. Athymic male nu/nu mouse approximately 4 hours after receiving IRDye 800CW PEG (1 nmol) intravenously.Large blood vessels and tumor are visible.
Figure 3. Athymic male nu/nu mouse approximately 9 hours after receiving IRDye 800CW PEG (1 nmol) intravenously. Tumor is clearly defined.
Figure 4. Athymic male nu/nu mouse minutes after receiving IRDye 800CW PEG (~0.1 nmole) intradermally on the tail (right side). Image highlights use of IRDye PEG as a lymph imaging agent.

References

  1. Vasey, P.A., et al. (1999) Clin, Cancer Res, 5:83-94.
  2. Matsumura, Y. and H. Maeda. (1986) Cancer Res, 46:6387-6392.
  3. Seymour, L.W. (1992) Crit. Rev. Ther. Drug Carrier Syst, 9(2):135-187.

Selected P/N: 926-50401

Price

Quantity

Add to Cart

+ Add to WishlistAdded. Go to Wishlist

Resources

chat iconChat With Us
chat icon disabled